Durvalumab,Tremelimumab
Astrazeneca
['nifty', '2mo', 'abc-06', '52mo', ' 100p']
 just presented our naliricc ph-ii at 52mo naliri/5fu vs 5-fu in 2nd line #cholangiocarcinoma, 100pts no benefit for adding nal-iri -&gt; tox? after abc-06 &amp; nifty, best 2nd line in btc still not well defined #livertwitter 
Physician-scientist, focussed on translational research in hepatobiliary cancer and precision medicine